VCM
JNCE

Versant Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Versant Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-81
Closed – – 1783
2019
Q4 		$0 Buy
+81
New +$438 ﹤0.01% 1656

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Versant Capital Management's JNCE Position: Q1 2020 in Review

Versant Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2020, closing a stake of 81 shares.

Versant Capital Management first reported a position in JNCE in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 88 funds tracked by Wall St. Rank hold JNCE as of Q1 2020.

  • Versant Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Versant Capital Management sold 81 Jounce Therapeutics, Inc. Common Stock shares in Q1 2020.
  • Versant Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Versant Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $0 in Q4 2019.
  • 88 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Versant Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.